Clinical trial NCT06941857: NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Official title: A Phase 2 Study of NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Treatment-naïve, Metastatic Pancreatic Cancer
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Pancreatic Cancer
Keywords: Nivolumab
Ipilimumab
NC410 (NextCure LAIR-2 (Leukocyte-Associated Immunoglobulin-like Receptor-2) fusion protein)
Oxaliplatin
Irinotecan
Folinic Acid
5-Fluorouracil
Folfirinox
Immunotherapy
Anti-PD-1 (anti-check point inhibitor)
PD-L1 (check point inhibitor)
Anti-CTLA-4 (anti-cytotoxic T-lymphocyte-associated antigen 4)
Metastatic Pancreatic Cancer
Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
Carcinoma
Pancreas
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor class: OTHER
Collaborators: name: NextCure, Inc.
name: Lustgarten Foundation
First posted: 2025-04-24
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
* Metastatic histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
* Have metastatic disease
* Must not have received prior systemic treatment for pancreatic cancer.
* Have measurable disease based on RECIST 1.1.
* Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures.
* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test.
* For both Women and Men, must use acceptable form of birth control while on study.
* Must understand the study regimen, its requirements, risks and discomforts and is able and willing to sign the informed consent form in accordance with regulatory and institutional guidelines.

Exclusion Criteria:

* Have had prior chemotherapy for pancreatic cancer or prior chemotherapy within 5 years of enrollment for other cancer diagnoses.
* Has received radiotherapy for pancreatic cancer.
* Are receiving or have received any investigational agent or used an investigational device within 28 days prior to Day 1 of treatment in this study.
* Has undergone major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis or an aborted Whipple), within 28 days prior to Day 1 of treatment in this study.
* Is expected to require any other form of systemic or localized antineoplastic therapy while on study.
* Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, or anti-Lag-3 antibodies.
* Has received a live vaccine or live-attenuated vaccine within 28 days prior to the first dose of study drug.
* Prior tissue or organ allograft regardless of need for immunosuppression, including corneal allograft.
* Has uncontrolled acute or chronic medical illness.
* Has history of central nervous system (CNS) metastases and/or carcinomatous meningitis.
* Has known additional malignancy that is progressing and requires active treatment.
* Has active autoimmune disease.
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent).
* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
* Requirement for daily supplemental oxygen.
* History of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases, chronic obstructive pulmonary disease (COPD), asthma requiring medication, etc.
* Known history of human immunodeficiency virus (HIV).
* Active or chronic hepatitis B or hepatitis C.
* Unable to undergo venipuncture and/or tolerate venous access.
* Has known psychiatric or substance use disorder that would interfere with cooperation with the requirements of the trial.
* Pregnant or breastfeeding
* A WOCBP who has a positive urine pregnancy test within 72 hours prior to study drug initiation.

Primary outcomes:
measure: Number of participants experiencing unexpected toxicities. Unexpected toxicities are toxicities related to the study drug required treatment discontinuation.
timeFrame: 4 years
Secondary outcomes:
measure: Progression- Free Survival (PFS)
timeFrame: 4 years
measure: Response Rate (ORR)
timeFrame: 4 years
measure: Disease Control Rate (DCR)
timeFrame: 4 years
measure: Overall Survival (OS)
timeFrame: 4 years
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Sidney Kimmel Comprehensive Cancer Center
state: Maryland
Study officials:
affiliation: SKCCC Johns Hopkins Medical Institution
name: Katherine Bever, MD
role: PRINCIPAL_INVESTIGATOR
References: